Chapter 28. Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications

  1. Lakshmi N. Yatham3 and
  2. Mario Maj4
  1. Chris J. Bushe1 and
  2. Mauricio Tohen2

Published Online: 13 AUG 2010

DOI: 10.1002/9780470661277.ch28

Bipolar Disorder

Bipolar Disorder

How to Cite

Bushe, C. J. and Tohen, M. (2010) Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications, in Bipolar Disorder (eds L. N. Yatham and M. Maj), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470661277.ch28

Editor Information

  1. 3

    Department of Psychiatry, The University of British Columbia, Vancouver, Canada

  2. 4

    Department of Psychiatry, University of Naples SUN, Naples, Italy

Author Information

  1. 1

    Lilly UK, Lilly House, Priestley Road, Basingstoke, RG24 9NL, UK

  2. 2

    University of Texas Health Science Center at San Antonio, 7730 Floyd Curl Drive, San Antonio, TX 78229, USA

Publication History

  1. Published Online: 13 AUG 2010
  2. Published Print: 1 OCT 2010

ISBN Information

Print ISBN: 9780470721988

Online ISBN: 9780470661277



  • bipolar disorder and safety monitoring for clinicians - review of evidence and implications;
  • bipolar disorder, complex disorder moving through phases - in patients;
  • metabolism and bipolar disorder - metabolic issues in bipolar disorder;
  • severe mental illness (SMI);
  • metabolic syndrome, entity not graded - no means of assessing worsening symptoms;
  • metabolic abnormalities, highest in schizoaffective patients;
  • lithium, dosing and toxicity - effective treatment in bipolar disorder associated with adverse events;
  • generic bipolar safety monitoring;
  • adverse events, associated with lithium treatment and toxicity;
  • lamotrigine, carbamazepine and valproate - and mucocutaneous syndromes


This chapter contains sections titled:

  • Introduction

  • Metabolism and bipolar disorder

  • Monitoring requirements for bipolar patients

  • Topical debates for years to come

  • Can safety monitoring for CVD risk factors improve?

  • Can wellness programmes in bipolar illness decrease CVD risk?

  • Implications for future monitoring and clinical research

  • Summary

  • Declaration of interest

  • Disclosure

  • References